IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
FEDERAL LOBBYING RECORDS

LOBBYING FILINGS AND MARKET CONTEXT

Indexed federal lobbying filings mapped to clients, registrants, and public-company tickers. Transaction dates are compared with filing periods to identify date-proximity review flags. Proximity does not establish coordination, influence, or wrongdoing.

Filings tracked
20,641
thru 2026-07-15
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,260
paying companies
Tickers targeted
1,219
public companies

Clients by reported amount

#ClientFilingsTotal $
1PFIZER INC.PFE48$46.9M
2GENERAL MOTORS COMPANYGM61$46.8M
3META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA13$45.0M
4VISA INC.V46$37.7M
5AMAZON.COM SERVICES LLCAMZN37$32.8M
6LOCKHEED MARTIN CORPORATIONLMT76$29.1M
7FEDEX CORPORATIONFDXW71$27.9M
8ELI LILLY AND COMPANYLLY60$27.4M
9ALTRIA CLIENT SERVICES LLCMO147$25.3M
10COMCAST CORPORATIONCMCSV183$24.9M
11AMGEN INCAMGN19$24.9M
12MERCK & CO INCMRK14$24.0M
13SOUTHERN COMPANYSO54$23.9M
14GOOGLE CLIENT SERVICES LLCGOOGL83$22.8M
15APPLE INCAAPL9$22.1M
16T-MOBILE USA INC.TMUS131$21.3M
17UNITEDHEALTH GROUP INCUNH19$20.4M
18VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ41$20.1M
19OCCIDENTAL PETROLEUM CORPORATIONOXY32$19.8M
20MICROSOFT CORPORATIONMSFT107$18.9M
21QUALCOMM INCORPORATEDQCOM40$17.2M
22BOEING COMPANYBA24$17.0M
23GENERAL DYNAMICS CORPGD11$17.0M
24THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI13$16.9M
25ORACLE CORPORATIONORCL60$16.8M

Mapped tickers by reported amount

#TickerFilingsTotal $
1META
Meta Platforms Inc.
134$50.3M
2PFE
Pfizer Inc.
89$48.7M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
47$37.7M
5AMZN
Amazon.com Inc.
82$35.4M
6LMT
Lockheed Martin Corporation
92$29.5M
7FDX
FedEx Corporation
83$28.4M
8LLY
Eli Lilly and Company
88$28.4M
9AMGN
Amgen Inc.
100$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
66$27.0M
12GOOGL
Alphabet Inc. Class A
128$26.8M
13MO172$26.4M
14SO
Southern Company
110$26.2M
15UNH
UnitedHealth Group Inc.
68$24.0M
16VZ
Verizon Communications Inc.
119$23.8M
17TMUS170$22.9M
18CHTR142$22.8M
19GD
General Dynamics Corporation
131$22.6M
20T
AT&T Inc.
137$21.7M
21ORCL
Oracle Corporation
135$20.8M
22CMCSA
Comcast Corporation
142$20.5M
23OXY
Occidental Petroleum Corporation
38$20.1M
24CI
The Cigna Group
64$19.9M
25MSFT
Microsoft Corporation
126$19.3M

🆕 Filtered Filings · PODD

clear filters
DateTickerClientRegistrantAmountIssue
2026-07-12PODDINSULET CORPORATIONTODD STRATEGY GROUP$60KGeneral education on diabetes care. General education about Insulet.
2026-04-20PODDINSULET CORPORATIONINSULET CORPORATION$140KIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plan
2026-04-20PODDINSULET CORPORATIONTODD STRATEGY GROUP$60KGeneral education on diabetes care. General education about Insulet.
2026-01-19PODDINSULET CORPORATIONINSULET CORPORATION$140KIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Is
2026-01-17PODDINSULET CORPORATIONTODD STRATEGY GROUP$50KGeneral education on diabetes care. General education about Insulet.
2025-10-17PODDINSULET CORPORATIONINSULET CORPORATION$110KIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS notice of proposed rule, DMEPOS Home Health Rule.
2025-10-12PODDINSULET CORPORATIONTODD STRATEGY GROUP$50KGeneral education on diabetes care. General education about Insulet.
2025-07-30PODDINSULET CORPORATIONTODD STRATEGY GROUP$40KGeneral education on diabetes care. General education about Insulet.
2025-07-21PODDINSULET CORPORATIONINSULET CORPORATION$130KIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act.
2025-07-21PODDINSULET CORPORATIONTODD STRATEGY GROUP$0General education on diabetes care. General education about Insulet.
2025-04-17PODDINSULET CORPORATIONINSULET CORPORATION$40KIssues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM).
2025-01-20PODDINSULET CORPORATIONINSULET CORPORATION$90KIssues related to the disease of diabetes, diabetes therapies and management of the disease of diabetes. Issues related to medical devices and medical device technology. Issues related to medical device sterilization methods. Issues related to Pharmacy Benefit Managers (PBMs) - no specific bills, but general discussions on impacts to medical devices in the pharmacy channel and impacts to patients. Issues in support of S.4532 H.R. 4532 - prior authorization reform. Issues related to real world evidence and real world data pertaining to medical devices and approval pathways. Issues related to artificial intelligence and predictive algorithms in medical device technology and innovations. Issues related to the filing of S. 5502 - DIABETES Act